Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N, Hellstrom I, Hellstrom KE.

Gynecol Oncol. 2012 Nov;127(2):412-9. doi: 10.1016/j.ygyno.2012.07.098. Epub 2012 Jul 22.

2.

A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions.

Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ.

J Clin Pathol. 2005 Oct;58(10):1096-100.

4.

Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix.

Monnier-Benoit S, Mauny F, Riethmuller D, Guerrini JS, Căpîlna M, Félix S, Seillès E, Mougin C, Prétet JL.

Gynecol Oncol. 2006 Jul;102(1):22-31. Epub 2006 Jan 20.

PMID:
16427684
5.

Accumulation of invariant NKT cells with increased IFN-γ production in persistent high-risk HPV-infected high-grade cervical intraepithelial neoplasia.

Hu T, Yang P, Zhu H, Chen X, Xie X, Yang M, Liu S, Wang H.

Diagn Pathol. 2015 Apr 2;10:20. doi: 10.1186/s13000-015-0254-8.

6.

Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.

Hildesheim A, Schiffman MH, Tsukui T, Swanson CA, Lucci J 3rd, Scott DR, Glass AG, Rush BB, Lorincz AT, Corrigan A, Burk RD, Helgesen K, Houghten RA, Sherman ME, Kurman RJ, Berzofsky JA, Kramer TR.

Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):807-13.

7.

Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.

Coutlée F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N, Ghatage P, Koushik A, Ferenczy A, Franco EL.

J Med Virol. 2011 Jun;83(6):1034-41. doi: 10.1002/jmv.22081.

PMID:
21503917
8.

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.

Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.

Cancer Immunol Immunother. 2004 Jul;53(7):642-50. Epub 2004 Feb 17.

9.

Relationship of up-regulation of 67-kd laminin receptor to grade of cervical intraepithelial neoplasia and to high-risk HPV types and prognosis in cervical cancer.

Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Syrjänen S, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Acta Cytol. 2006 Jan-Feb;50(1):6-15.

PMID:
16514834
10.
11.

Human papillomavirus L1 capsid protein and human papillomavirus type 16 as prognostic markers in cervical intraepithelial neoplasia 1.

Choi YS, Kang WD, Kim SM, Choi YD, Nam JH, Park CS, Choi HS.

Int J Gynecol Cancer. 2010 Feb;20(2):288-93. doi: 10.1111/IGC.0b013e3181cd184c.

PMID:
20134272
12.

T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.

Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P, Man S.

Clin Vaccine Immunol. 2010 Sep;17(9):1315-21. doi: 10.1128/CVI.00105-10. Epub 2010 Jul 28.

13.

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.

Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM.

Int J Cancer. 2012 Nov 15;131(10):2349-59. doi: 10.1002/ijc.27485. Epub 2012 Mar 20.

14.

Epidemiology of cervical intraepithelial neoplasia: the role of human papillomavirus.

Cox JT.

Baillieres Clin Obstet Gynaecol. 1995 Mar;9(1):1-37. Review.

PMID:
7600720
15.

Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer.

Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):223-31. Epub 2006 Nov 13.

PMID:
17098349
16.

The role of mRNA E6/E7 HPV high oncogenic risk expression in colposcopy of cervical intraepithelial neoplasia (CIN).

Galarowicz B, Jach R, Kidzierska J, Dyduch G, Zajac K, Pityński K, Banaś T, Huras H, Streb J, Dulińska-Litewka J, Hosiawa V, Juszczak M, Milewicz T.

Przegl Lek. 2012;69(9):651-7.

PMID:
23401983
17.

Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.

Sánchez-Lander J, Cortiñas P, Loureiro CL, Pujol FH, Medina F, Capote-Negrín L, Bianchi G, García-Barriola V, Ruiz-Benni A, Avilán-Rovira J, Acosta H.

Cancer Epidemiol. 2012 Oct;36(5):e284-7. doi: 10.1016/j.canep.2012.04.005. Epub 2012 May 17.

PMID:
22608058
18.

Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix.

Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):233-7.

19.

Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.

Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S, Carlani A, Staiano M, D'Amico MR, D'Angelo V, Di Dato E, Martinelli N, Malaspina M, Spita N, Tintori B, Fulciniti F.

Acta Cytol. 2012;56(5):506-14. doi: 10.1159/000338979. Epub 2012 Sep 27.

PMID:
23075891
20.

Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection.

Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, Venzon DJ, Shearer GM, De Palo G, Clerici E.

J Natl Cancer Inst. 1997 Feb 5;89(3):245-50.

PMID:
9017005

Supplemental Content

Support Center